Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.
/PRNewswire/ The "Dermatitis Global Market Report 2023" report has been added to ResearchAndMarkets.com s offering. The global dermatitis market will grow.
Li Peng, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Announcing the finalists for the 2022 BioBuzz Awards. Vote in 6 Categories for doers making an impact in the BioHealth Capital Region and Greater Philadelphia.
NEWS RELEASE - Emmes Hires Ching Tian in New Leadership Role to Accelerate Innovation &.